A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.

Opdivo (nivolumab) - Ono Pharma, BMS

isunakinra (EBI-005) - Buzzard Pharma

Carlos Roberto Becerra; Andrew Scott Paulson; Jan Kowalski; Hans Olivecrona; Maarten de Chateau

Apr 27, 2023